United States· US:50881-006_232fcac8-b438-4872-8ef1-6332ecdf9304
ZYNYZ
A medicinal product containing retifanlimab, registered in United States by Incyte Corporation.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RETIFANLIMAB
- Manufacturer
- Incyte Corporation
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1150881-006-03
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Retifanlimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandZYNYZ 500 mg/20 ml, solution à diluer pour perfusionIncyte Biosciences International Sàrl
- CzechiaZYNYZIncyte Biosciences Distribution B.V., Amsterdam
- SpainZYNYZ 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONIncyte Biosciences Distribution B.V.
- FinlandZYNYZIncyte Biosciences Distribution B.V.
- IrelandZynyz 500 mg concentrate for solution for infusionIncyte Biosciences Distribution B.V.
- BelgiumZynyz 500 mgIncyte Biosciences Distribution
- Japanレチファンリマブ（遺伝子組換え）インサイト・バイオサイエンシズ・ジャパン
- NetherlandsZYNYZ 500 mg concentraat voor oplossing voor infusieIncyte Biosciences Distribution B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zynyz
- Liechtenstein · Zynyz
- Norway · Zynyz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3c662b6e-4ec7-4f1d-97a4-316d7b999bcb GET /v1/drugs/3c662b6e-4ec7-4f1d-97a4-316d7b999bcb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "25",
"substance": "RETIFANLIMAB",
"productndc": "50881-006",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761334",
"marketing_category": "BLA"
}See everything about retifanlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.